IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit

     IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit

Funds Released from Escrow Account Marks Final Chapter in Sale

PR Newswire

MOUNTAIN VIEW, Calif., May 16, 2013

MOUNTAIN VIEW, Calif., May 16, 2013 /PRNewswire/ --IRIDEX Corporation
(Nasdaq:IRIX) today announced that it has received the final $510,000 cash
payment from the February 2012 sale of its aesthetic business unit. The cash
was released to IRIDEX from an escrow account set up as part of the
transaction.

"The release of the funds from escrow marks the final chapter in the sale of
our aesthetics business," said IRIDEX President and CEO Will Moore. "The sale
has been a successful transaction. It's great to have the final milestone
behind us and have the funds added to our cash balance. We continue to explore
new business opportunities and relationships to leverage our cash and
technology resources to grow the business."

Moore added that the $510,000 in escrow had previously been reported on the
Company's financial statements as part of current assets from discontinued
operations.

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in
developing, manufacturing, and marketing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation for the
ophthalmology market. We maintain a deep commitment to the success of our
customers, with comprehensive technical, clinical, and service support
programs. IRIDEX is dedicated to a standard of excellence, offering superior
technology for superior results. IRIDEX products are sold in the United States
through a direct sales force and internationally through a combination of a
direct sales force and a network of approximately 70 independent distributors
into over 100 countries. For further information, visit the IRIDEX website at
http://www.iridex.com/.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Act of 1934, as amended, relating to the Company's strategic growth
plans and opportunities. These statements are not guarantees of future
performance and actual results may differ materially from those described in
these forward-looking statements as a result of a number of factors. Please
see a detailed description of these and other risks contained in our Annual
Report on Form 10-K for the fiscal year ended December 29, 2012 and Quarterly
Report on Form 10-Q for the fiscal quarter ended March30, 2013 which were
filed with the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date and will not be
updated.

SOURCE IRIDEX Corporation

Website: http://www.iridex.com
Contact: IRIDEX Contact: Jim Mackaness CFO & COO 650-940-4700; or Investor
Relations Contact: Matt Clawson, Allen & Caron, 949-474-4300,
matt@allencaron.com
 
Press spacebar to pause and continue. Press esc to stop.